Article: Nicotinamide Riboside Supplementation with Metabolic Activators Improves Cognitive Function in Parkinson’s Disease: Clinical Findings

Clinical Neurological Health Parkinson's Disease

Nicotinamide Riboside Supplementation with Metabolic Activators Improves Cognitive Function in Parkinson’s Disease: Clinical Findings

Objectives

To investigate whether supplementation of combined metabolic activators (CMA) consisting of NR, L-carnitine tartrate, serine, and N-acetyl-L-cysteine (NAC), could be used to treat Parkinson's disease (PD) patients.

Journal

Brain Communications

Key Outcomes

CMA supplementation did not improve motor function in PD patients.
CMA significantly improved cognitive function, particularly in patients with low baseline MoCA scores, indicative of worsened cognitive function. However, the variability in baseline MoCA scores likely influenced the observed outcomes.

Duration

12 weeks

Dose

2000 mg*
*One dose of 1 g NR, 12.35 g L-serine, 2.55 g N-acetyl-L-cysteine, and 3.73 g L-carnitine tartrate for the first 28 days and two doses for the next 56 days.

Study Design

Randomized, double-blind, placebo-controlled, phase II study in 48 Parkinson's disease (PD) patients

See Published Study

Ataxia Telangiectasia

Nicotinamide Riboside Supplementation Improves Motor Coordination and Eye Movements in Children with Ataxia Telangiectasia: Clinical Findings

Objectives To examine the safety and efficacy of long-term NR supplementation on neuromotor function in patients with ataxia telangiectasia (AT). Journal Movement Disorders Key Outcomes Long-ter...

Alzheimer's Disease

Nicotinamide Riboside Supplementation Improves Alzheimer's Biomarkers in Subjective Cognitive Decline and Mild Cognitive Impairment: Clinical Findings

Objectives To test the safety and efficacy of oral NR supplementation on cognition and Alzheimer's disease (AD) blood biomarkers in older adults with subjective cognitive decline and mild cognitiv...